16% local currency operating profit growth adjusted for the NNIT divestment
Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion.
-
Sales of Victoza® increased by 41% (22% in local currencies).
-
Sales of Levemir® increased by 28% (10% in local currencies).
-
Sales in North America increased by 35% (10% in local currencies).
-
Sales in International Operations increased by 26% (17% in local currencies).
-
Sales in Region China increased by 25% (3% in local currencies).
Gross margin improved by 2.2 percentage points in Danish kroner to 85.2% driven by a positive currency impact and product mix.
Operating profit increased by 57% in Danish kroner and by 30% in local currencies to DKK 26.3 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 16%.
Net profit increased by 35% to DKK 18.2 billion. Diluted earnings per share increased by 38% to DKK 7.02. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 20% and 22% respectively.
In July, Novo Nordisk announced the successful completion of the first phase 3a trial with semaglutide, a new GLP-1 analogue to be administered subcutaneously once weekly.
Novo Nordisk successfully completed the first phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes, in July.
For 2015, sales growth measured in local currencies is still expected to be 7-9%, whereas operating profit growth measured in local currencies is raised by two percentage points and now expected to be around 19%.
Lars Rebien Sørensen, President and CEO: "We are satisfied with the results of the first six months of 2015, during which Victoza® and Levemir® continued to drive sales growth. In the second quarter, we have successfully launched NovoEight® and Saxenda® in the US and announced positive results from the first phase 3a trial for semaglutide, our once-weekly GLP-1 analogue."
Contacts for further information
| Media: | ||
| Katrine Sperling | +45 3079 6718 | |
| Ken Inchausti (US) | +1 609 514 8316 | |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | |
| Daniel Bohsen | +45 3079 6376 | |
| Melanie Raouzeos | +45 3075 3479 | |
| Frank Daniel Mersebach (US) | +1 609 235 8567 |
Company announcement No 46 / 2015
Company announcement No 46 / 2015
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
HUG#1943925